Project description DEENESFRITPL Regulatory T cells therapy for graft versus host disease Haematopoietic stem cell transplantation (HSCT) is the gold standard treatment for various blood disorders including haematological malignancies. However, in a significant proportion of transplanted individuals the donor's immune system attacks the patient's tissues, a condition known as graft versus host disease (GVHD). Given the role of regulatory T cells in controlling immune responses, the EU-funded TREGeneration project proposes to use donor-derived regulatory T cells as a therapeutic treatment for GVHD. The consortium will investigate different regulatory T cell preparation strategies, determine the necessity of in vitro expansion, and explore the potential benefits of co-administering therapeutic agents. Insight into the mechanisms underlying regulatory T cell therapy will help the treatment of other diseases. Show the project objective Hide the project objective Objective Our proposal encompasses parallel clinical trials addressing the feasibility and the effectiveness of donor-derived regulatory T cells (Treg) as a therapeutic agent in the treatment and prevention of tissue and organ damage resulting from graft versus host disease (GVHD) after hematopoietic stem cell transplantation (HSCT).We propose a collaborative clinical study in which Treg therapy for GHVD is the common dominator. However, by bringing together several clinical centers with expertise in this area, we are also having the opportunity to simultaneously address other issues that would not otherwise be addressable by each clinical center on its own. Firstly, by using different Treg preparation strategies, we will be able to determine whether ex vivo isolated Treg are sufficient or whether in vitro expansion and subsequently higher dosages are required. Secondly, we will investigate if sole Treg infusion is effective or if rather co-administration of therapeutic agents that are likely to induce Treg survival and expansion in vivo (rapamycin; IL-2) is required for a successful response to Treg therapy.The studies on GVHD treatment outcome will be pursued together with a detailed analysis of immune monitoring, comprising T cell receptor clonotype tracking and tissue regeneration markers, in order to further understand the mechanisms underlying the therapeutic and regenerative potential of Treg cells. Our consortium has developed a concerted approach to the topic of Treg therapy in GVHD. This is a unique opportunity to determine the validity of this cellular immunotherapy approach in GVHD prevention and treatment, with potential for a significant impact on patient quality of life, survival rate and ultimately on the quality of health care provided. Fields of science medical and health sciencesmedical biotechnologycells technologiesstem cellsmedical and health sciencesclinical medicineemergency medicinegraft versus host diseasemedical and health sciencesclinical medicinetransplantation Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) PHC-15-2014 - Clinical research on regenerative medicine Call for proposal H2020-PHC-2014-2015 See other projects for this call Sub call H2020-PHC-2014-single-stage Funding Scheme RIA - Research and Innovation action Coordinator INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES Net EU contribution € 1 886 979,18 Address Avenida prof egas moniz 1649 028 Lisboa Portugal See on map Region Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 Participants (8) Sort alphabetically Sort by Net EU contribution Expand all Collapse all KLINIKUM DER UNIVERSITAET REGENSBURG Germany Net EU contribution € 1 423 823,75 Address Frans josef strauss allee 11 93053 Regensburg See on map Region Bayern Oberpfalz Regensburg, Kreisfreie Stadt Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 UNIVERSITE DE LIEGE Belgium Net EU contribution € 241 742,78 Address Place du 20 aout 7 4000 Liege See on map Region Région wallonne Prov. Liège Arr. Liège Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 IRCCS AZIENDA OSPEDALIERO- UNIVERSITARIA DI BOLOGNA Italy Net EU contribution € 627 452,50 Address Via albertoni 15 40138 Bologna See on map Region Nord-Est Emilia-Romagna Bologna Activity type Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV Germany Net EU contribution € 741 335,00 Address Hofgartenstrasse 8 80539 Munchen See on map Region Bayern Oberbayern München, Kreisfreie Stadt Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 ALACRIS THERANOSTICS GMBH Germany Net EU contribution € 277 500,00 Address Max planck strasse 3 12489 Berlin See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Berlin Berlin Berlin Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 THE UNIVERSITY OF LIVERPOOL United Kingdom Net EU contribution € 246 077,50 Address Brownlow hill 765 foundation building L69 7ZX Liverpool See on map Region North West (England) Merseyside Liverpool Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG Participation ended Germany Net EU contribution € 88 919,29 Address Oskar von miller ring 29 80333 Muenchen See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Bayern Oberbayern München, Kreisfreie Stadt Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 SERVICIO ANDALUZ DE SALUD Spain Net EU contribution € 365 420,00 Address Avenida de la constitucion 18 41071 Sevilla See on map Region Sur Andalucía Sevilla Activity type Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00